⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8266675 | 1.00 | — | — | |
| SCHEMBL15374300 | 1.00 | — | — | |
| SCHEMBL16126106 | 0.81 | TP53 (0.33) | — | |
| SCHEMBL16126104 | 0.81 | TP53 (0.33) | — | |
| SCHEMBL16126125 | 0.81 | TP53 (0.33) | — | |
| SCHEMBL16126126 | 0.81 | TP53 (0.33) | — | |
| SCHEMBL18884727 | 0.81 | TP53 (0.33) | — | |
| SCHEMBL16126131 | 0.81 | TP53 (0.33) | — | |
| SCHEMBL16158854 | 0.81 | TP53 (0.33) | — | |
| SCHEMBL18884728 | 0.81 | TP53 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2673242-B1 | HYDROPHOBING DISPERSION GEL, METHOD FOR PRODUCING SAME, AND USE THEREOF FOR THE DEEP HYDROPHOBING OF MINERAL MATERIALS | IONYS AG (DE) | 2015-05-06 | — | — | EP | claimed |
| US-7235258-B1 | Sustained-release formulations for treating CNS-mediated disorders | NPS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | claimed |
| EP-1576962-A1 | Composition comprising isovaleramide and ibuprofen | NPS PHARMACEUTICALS, INC. (US) | 2005-09-21 | — | — | EP | claimed |
| US-20040072900-A1 | Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound | NPS PHARMACEUTICALS | 2004-04-15 | — | — | US | claimed |
| CN-1409630-A | Sustainable-release formulations for treating CNS-mediated disorders | NPS PHARMA INC (US) | 2003-04-09 | — | — | CN | claimed |
| JP-2002538106-A | — | — | 2002-11-12 | — | — | JP | claimed |
| EP-1225888-A2 | SUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS-MEDIATED DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2002-07-31 | — | — | EP | claimed |
| US-6383527-B1 | FOR TREATMENT OF ACUTE MUSCULAR ACHES, STRAINS, AND SPRAINS WHICH OCCUR FROM A LOCALIZED, EXTERNAL INSULT TO A PARTICULAR MUSCLE OR MUSCLE GROUP | NPS PHARMACEUTICALS, INC. | 2002-05-07 | — | — | US | claimed |
| EP-1176953-A2 | TREATMENT OF A VARIETY OF PATHOLOGICAL CONDITIONS, INCLUDING SPASTICITY AND CONVULSIONS, BY EFFECTING MODULATION OF CNS ACTIVITY WITH ISOVALERAMIDE, ISOVALERIC ACID, OR A RELATED COMPOUND | NPS PHARMACEUTICALS, INC. (US) | 2002-02-06 | — | — | EP | claimed |
| EP-1144368-A2 | ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | American Cyanamid Company (US) | 2001-10-17 | — | — | EP | claimed |
| WO-2001028516-A2 | SUSTAINED-RELEASE FORMULATIONS FOR TREATING CNS-MEDIATED DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2001-04-26 | — | — | WO | claimed |
| EP-1059930-A1 | COMPOSITIONS COMPRISING VALERIAN EXTRACTS, ISOVALERIC ACID OR DERIVATIVES THEREOF WITH A NSAID | NPS PHARMACEUTICALS, INC. (US) | 2000-12-20 | — | — | EP | claimed |
| WO-2000051586-A2 | TREATING A VARIETY OF PATHOLOGICAL CONDITIONS, INCLUDING SPASTICITY AND CONVULSIONS, BY EFFECTING MODULATION OF CNS ACTIVITY WITH ISOVALERAMIDE, ISOVALERIC ACID, OR A RELATED COMPOUND | NPS PHARMACEUTICALS, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| WO-2000044709-A2 | ACETYLENIC α-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | claimed |
| WO-1999044623-A1 | COMPOSITIONS COMPRISING VALERIAN EXTRACTS, ISOVALERIC ACID OR DERIVATIVES THEREOF WITH A NSAID | NPS PHARMACEUTICALS, INC. (US) | 1999-09-10 | — | — | WO | claimed |
| US-4464539-A | FROM ALPHAHYDROXY AMIDES USING PHOSPHATE CATALYSTS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1984-08-07 | — | — | US | claimed |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | Nxera Pharma UK Limitied (GB) | 2025-08-19 | — | — | US | disclosed |
| US-4464539-A | FROM ALPHAHYDROXY AMIDES USING PHOSPHATE CATALYSTS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4222960-A | Process for the manufacture of α-hydroxycarboxylic acid amides | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1980-09-16 | — | — | US | disclosed |